Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 20 Dec 2019 |
| Genmab and CureVac Enter Strategic Partnership to Develop mRNA-based Antibody Therapeutics | 19 Dec 2019 |
| Genmab A/S has published its Articles of Association | 17 Dec 2019 |
| CHMP Issues Positive Opinion Recommending DARZALEX® (Daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma | 13 Dec 2019 |
| Genmab to Hold 2019 R&D Update and ASH Data Review Meeting | 9 Dec 2019 |
| Genmab Achieves USD 100 Million Sales Milestone in DARZALEX® (daratumumab) Collaboration with Janssen | 5 Dec 2019 |